BackgroundAtopic dermatitis (AD) may cause emotional distress and impairs the quality of life (QoL) in children and their families.ObjectiveWe examined family QoL of children with AD and explored associated factors such as disease severity and psychosocial factors among parents of children with AD.MethodsStudy participants were 78 children (1 month to 16 years old) diagnosed with AD and their parents visiting an outpatient clinic of the Department of Pediatrics in Inha University Hospital. Data were collected using structured questionnaires and medical record review. Parents completed the Dermatitis Family Impact questionnaire (DFI), the Positive Affect and Negative Affect Schedule, the Satisfaction with Life Scale, and the Korean Parenting Stress Index. For children aged below 6-year-old, parents were asked to complete the Infants' Dermatologic Quality of Life. SCOring Atopic Dermatitis (SCORAD), Children's Dermatology Life Quality Index, and the Pediatric Quality of Life Inventory version 4.0 Generic Core Scale were also completed.ResultsThe mean age of parents and children were 37.4 ± 5.3 years and 65.1 ± 45.7 months, respectively. Among them, 87.2% of parents were mothers and 60.3% of children were boys. The mean score of DFI was 11.2 ± 6.0. The mean SCORAD score was 28.3 ± 16.1. Family who experienced strong negative emotionality had a 3.8 times higher probability of experiencing a lower QoL than parents who did not (odds ratio [OR], 3.82; p = 0.041). Family of children with higher severity of AD had a 6.6 times (OR, 6.55; p = 0.018) higher probability of experiencing a low family QoL than their less-severe counterparts. Families of girls with AD had a lower QoL (OR, 8.40; p = 0.003) than families of boys.ConclusionFamily QoL among parents of children with AD was low and associated with parent’s psychosocial characteristics as well as disease severity of the children. Considering parental involvement in AD management for children, emotional support for parents can be helpful in long journey of disease management.
The first patient of Middle East respiratory syndrome caused by a novel coronavirus infection in Korea was confirmed on May 20, 2015. After that, MERS spread over the country. In recent years, patients of MERS have been found around the Arabian Peninsula and the case fatality ratio of MERS in those area was been reported to range from 30 to 40%. In this paper, we estimate the case fatality ratio of MERS of Korea using data of 186 infections until December 1, 2015. In this study we propose a novel estimator of the case fatality ratio using information of the patients severity condition as well as records on the days of confirmation and death or recovery of the patient. By using publicly available data of the Department of Health and Human Services Centers for Disease Control, we evaluate a performance of the estimator and demonstrate a stability of the estimator from the early stage of the epidemic.
In an early stage of the course of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) outbreak in Korea in 2015, the Centers for Disease Control and Prevention of Korea and several studies reported estimated Case Fatality Ratios (CFRs) that were significantly different. Here, we propose an estimation method based on the commonly quoted naive estimator of CFR utilizing the number of in-hospital patients with comorbidities, as well as the numbers of cumulative confirmed and dead patients up to a certain date. We compared the proposed estimator with two naive and an integral method estimator by simulation experiments under the individual based susceptible-exposed-infected-recovered model and analysis of data from the 2015 epidemic of MERS-CoV in Korea. The proposed estimator better simulated and analyzed the Korean MERS data.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.